This week brought major news about GLP-1 drugs like Ozempic and Wegovy. Beyond their well-known effects on weight and diabetes, researchers are discovering these medications may protect against liver cancer, reduce epilepsy risk, and even help preserve memory—while new studies reveal both promising benefits and unexpected risks.
🎯 GLP-1 drugs cut liver cancer risk nearly in half
A massive analysis of over 2.2 million patients found GLP-1 receptor agonists reduced hepatocellular carcinoma risk by 42% compared to other diabetes treatments
The protection was strongest when compared to insulin (71% risk reduction) and most pronounced in patients without cirrhosis (59% reduction)
The number needed to treat ranged from just 24 to 476 patients, meaning relatively few people need treatment to prevent one case of liver cancer
Why it matters: This suggests GLP-1 drugs may offer substantial cancer protection beyond their metabolic benefits, particularly important since 70% of diabetes patients also have fatty liver disease—a major liver cancer risk factor.
Top 20% journal 🔗 Cancer medicine Network Meta-Analysis 🗓️ Dec 13
Key Findings
🧠 Epilepsy risk drops 16% with GLP-1 therapy
Among 452,766 diabetes patients, those taking GLP-1 drugs had 16% lower epilepsy risk compared to other diabetes medications
The protective effect was strongest at one year (29% reduction) and persisted at 3 and 5 years
Semaglutide showed the most impressive results with 32% lower epilepsy risk
💡 These findings suggest GLP-1 drugs may offer unexpected brain protection beyond blood sugar control.
🥉 Top 5% journal 🔗 Neurology Journal Article 🗓️ Dec 10
💊 Cancer fears may be overblown
Analysis of 48 trials with 94,245 participants found GLP-1 drugs probably have little to no effect on major cancer risks
Thyroid cancer risk showed no significant increase (1 fewer to 9 more cases per 10,000 patients)
Results were consistent across different drug types, doses, and patient populations
💡 This large-scale evidence may help reassure patients and doctors about cancer safety concerns.
🥈 Top 2% journal 🔗 Annals of internal medicine Review 🗓️ Dec 8
🔬 Suicide risk analysis shows mixed results
Meta-analysis of 12 studies found no significant difference in suicidal thoughts between GLP-1 users and other diabetes/obesity drugs
However, liraglutide users had 48% higher suicide risk compared to semaglutide users in subgroup analysis
No significant difference was found between semaglutide and newer drug tirzepatide
💡 While overall suicide risk appears similar to other treatments, differences between specific GLP-1 drugs warrant further investigation.
Top 50% journal 🔗 Medicine Meta-Analysis 🗓️ Dec 10
⚖️ Real-world weight loss matches clinical trials
Analysis of 655 patients using semaglutide via telehealth achieved 16.6% average weight loss over 68 weeks
Women had significantly better outcomes, with higher odds of achieving 5%, 10%, and 20% weight loss targets
Most common side effects were nausea/vomiting (37.3%) and constipation (15.6%), with no new safety signals
💡 Telehealth delivery of GLP-1 drugs can achieve trial-level weight loss, potentially expanding access to effective obesity treatment.
🎖️ Top 10% journal 🔗 Obesity (Silver Spring, Md.) Journal Article 🗓️ Dec 10
🫀 Heart failure benefits confirmed
Meta-analysis showed GLP-1 and dual GLP-1/GIP drugs reduced risk of worsening heart failure and composite cardiovascular endpoints
Benefits were seen in patients with heart failure with preserved ejection fraction, a difficult-to-treat condition
No significant differences in overall death rates, but cardiovascular event reduction was consistent
💡 These drugs may offer heart protection beyond weight loss, particularly for patients with specific types of heart failure.
Top 30% journal 🔗 Clinical Cardiology Meta-Analysis 🗓️ Dec 13
💰 Cost-effectiveness concerns emerge
Economic analysis of 9 studies found GLP-1 drugs generally not cost-effective for obesity treatment in patients without diabetes
Semaglutide and liraglutide showed negative cost-benefit ratios compared to lifestyle interventions and no treatment
However, longer treatment periods and broader health benefits may improve cost-effectiveness in certain subgroups
💡 High drug costs may limit widespread adoption for obesity alone, highlighting the need for better pricing or identification of patients most likely to benefit.
🥉 Top 5% journal 🔗 Diabetes, obesity & metabolism Journal Article 🗓️ Dec 9
Implications
GLP-1 drugs are emerging as surprisingly versatile medications with benefits extending far beyond diabetes and weight loss—from liver cancer prevention to brain protection. However, questions remain about cost-effectiveness, optimal patient selection, and long-term safety profiles that will shape how these powerful drugs are used in the future.
